AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose expansion cohort
Description: Dose of PY159 as a single agent given for predefined tumor histology
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 1
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study NCT02487563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine
Study NCT02487563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO
Study NCT02487563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: immunoglobulin, glucocorticoid etc
Study NCT01130766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery (SRS)
Description: Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
Study NCT02784535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: norepinephrine transporter inhibitor
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 2
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 3
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study NCT02784535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 4
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 5
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 6
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study NCT03806218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar RFA
Description: Bipolar RFA in which RF currents flow between two electrodes
Study NCT03806218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SM-RFA
Description: Monopolar RFA using multiple electrodes with switching mode
Study NCT03806218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin internally cooled-wet electrodes
Description: Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
Study NCT03806218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Separable clustered electrodes
Description: A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
Study NCT04301518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention strategy
Description: * Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation
Study NCT04386668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let It Out (LIO)-C
Description: Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
Study NCT04386668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral writing control
Description: Participants complete three online 20-minute writing sessions in response to neutral writing prompts
Study NCT02328807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-Frequency Ablation (RFA)
Description: RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
Study NCT01448265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation.
Description: Cryoballoon ablation using a novel circular mapping catheter.
Study NCT03396653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer-delivered Weight Maintenance
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
Study NCT03396653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professionally-Delivered Weight Maintenance
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
Study NCT03012997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 40%
Study NCT03012997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 100%
Study NCT03389932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Guided
Description: Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 420 mg administered by IV infusion Q2W.
Study NCT04158167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxytocin
Description: 24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion Q2W.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
Study NCT02943954 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography guided PCI
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
Study NCT04567745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Retinal fundus photography
Description: Fundus photographs
Study NCT02943954 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional Flow Reserve (FFR)
Study NCT02340429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DE500 Digital Video Otoscope
Study NCT02204215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric acupuncture
Description: Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
Study NCT02641795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive robotic cochlear implantation
Study NCT02204215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative
Description: General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
Study NCT01721967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study NCT00626587 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)
Description: The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
Study NCT02076932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning
Description: After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
Study NCT02076932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spinning
Description: After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
Study NCT03440580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BOOSTH
Description: BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
Study NCT02516371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lymphocyte
Description: To evaluate the subpopulation of lymphocytes in cancer patients
Study NCT02223299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-tyrosine
Description: 6g/d daily for 30 days
Study NCT01116271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 50 or 75mg, capsules, PO, BID, 28 days
Study NCT04146454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-based balance exercises
Description: A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
Study NCT04521439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: 18F-florbetapir PET+MRSI
Description: PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
Study NCT04521439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-florbetapir PET+MRSI
Description: PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
Study NCT06379022 — intervention group
Intervention type: BEHAVIORAL
Intervention: Plaque control
Description: Subjects are motivated for optimal oral hygiene
Study NCT01116271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m2, IV, Day 1\& 15 of each cycle
Study NCT02452944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve stimulator (stimuplex HNS12)
Description: whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
Study NCT02452944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulator (stimuplex HNS12)
Description: whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
Study NCT02452944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
Study NCT02452944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
Study NCT00391768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir (Tamiflu®)
Description: Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
Study NCT03686059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: daily intake of 250 mg
Study NCT03686059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: punctal plug
Description: punctal plug will be inserted in inferior punctum
Study NCT00659581 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Description: Oral administration
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: G-CSF support for four doses.
Study NCT04584112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Description: GM-CSF support for four doses.
Study NCT03719872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative Transabdominal Ultrasound
Description: Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
Study NCT03719872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Post-Operative Transabdominal Ultrasound
Description: Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
Study NCT04536636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docohexanoic acid
Description: Patients received 650 mg DHA/3 times/wk/post-HD session
Study NCT04536636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control-No drug
Description: Patients received usual medical care with no DHA
Study NCT03151265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermaCare Low Back Heat Wrap
Description: The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
Study NCT03339076 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: M3 MINI CATHETER
Description: Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter.
Study NCT03821376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound with Lumason
Description: Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
Study NCT03313479 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given with GS
Study NCT02874638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BASE egg protein
Description: 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
Study NCT02874638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA-enriched egg protein
Description: BCAA-enriched egg protein provided as crystalline amino acid.
Study NCT02874638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: small amount of essential amino acids
Description: essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
Study NCT02874638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: large amount of essential amino acids
Description: essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
Study NCT01339858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
Study NCT01339858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
Study NCT01566669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
Study NCT01566669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
Study NCT02223299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Tryptophan
Description: 2g/d daily for 30 days
Study NCT00738010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab
Description: Program of NMES 3 times per day, five days per week for 12 weeks.